AP Biosciences Inc (6945.TWO)
TWD 49.6
(0.51%)
TWD 49.6
(0.51%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Operating Cash Flow | -297.61 Million | -275.97 Million | -168.68 Million | -17.04 Thousand |
| Net Income | -339.29 Million | -288.53 Million | -187.6 Million | 41.74 Thousand |
| Depreciation & Amortization | 12.57 Million | 8.67 Million | 8.85 Million | 7200.00 |
| Deferred income taxes | - | - | - | - |
| Stock-based compensation | 24.74 Million | 28.99 Million | 2.94 Million | 5997.00 |
| Change in working capital | 3.56 Million | -24.21 Million | 7.12 Million | -71.98 Thousand |
| Other non-cash items | -8.82 Million | -2.58 Million | -212 Thousand | -270.00 |
| Investing Cash Flow | -468.67 Million | -3.14 Million | -34.91 Million | -7303.00 |
| Investments in PPE | -35.41 Million | -2.43 Million | -4.91 Million | -7250.00 |
| Acquisitions | - | - | - | - |
| Investment purchases | -461.41 Million | -30.71 Million | -30 Million | - |
| Sales/Maturities of investments | 30.71 Million | 30 Million | - | - |
| Other Investing Activities | -2.56 Million | -2000.00 | -5000.00 | -53.00 |
| Financing Cash Flow | -3.1 Million | 800 Million | 100 Million | 581.11 Thousand |
| Debt repayment | -3.1 Million | - | - | - |
| Dividends payments | - | - | - | - |
| Common Stock Repurchased | - | - | - | - |
| Common Stock Issuance | - | 800 Million | 100 Million | 581.11 Thousand |
| Other Financing Activities | -3.1 Million | 800 Million | - | - |
| Accounts receivables | -2.31 Million | - | - | - |
| Accounts payables | - | - | - | - |
| Inventory | - | - | - | - |
| Other working capital | -11.01 Million | -7.62 Million | - | - |
| Cash at beginning of period | 1.04 Billion | 527.12 Million | 630.72 Million | 73.96 Thousand |
| Cash at end of period | 278.6 Million | 1.04 Billion | 527.12 Million | 630.72 Thousand |
| Capital Expenditure | -35.41 Million | -2.43 Million | -4.91 Million | -7250.00 |
| Effect of forex changes on cash | - | - | - | - |
| Net cash flow / Change in cash | -769.39 Million | 520.88 Million | -103.6 Million | 556.76 Thousand |
| Free Cash Flow | -333.02 Million | -278.4 Million | -173.59 Million | -24.29 Thousand |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -113.13 Million | -113.13 Million | -110.6 Million | -339.29 Million | -110.6 Million | -59.04 Million |
| Depreciation & Amortization | 4.03 Million | 4.03 Million | 4.01 Million | 12.57 Million | 4.01 Million | 1.78 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 12.49 Million | - | 6.2 Million | 24.74 Million | 6.2 Million | 6.17 Million |
| Change in working capital | -1.66 Million | -1.4 Million | -4.02 Million | 3.56 Million | -4.02 Million | -1.48 Million |
| Other non-cash items | 323.5 Thousand | 12.56 Million | 2.43 Million | -8.82 Million | 2.43 Million | 5.74 Million |
| Investing Cash Flow | 180.04 Million | 180.04 Million | -11.8 Million | -468.67 Million | -11.8 Million | -222.53 Million |
| Investments in PPE | -657.5 Thousand | -657.5 Thousand | -12.52 Million | -35.41 Million | -12.52 Million | -4.99 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | -461.41 Million | - | - |
| Sales/Maturities of investments | - | - | - | 30.71 Million | - | - |
| Other Investing Activities | 180.7 Million | 180.7 Million | 713.5 Thousand | -2.56 Million | 713.5 Thousand | -217.53 Million |
| Financing Cash Flow | 598.91 Million | 598.91 Million | -1.55 Million | -3.1 Million | -1.55 Million | - |
| Debt repayment | - | - | - | -3.1 Million | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 598.91 Million | 598.91 Million | -1.55 Million | - | -1.55 Million | - |
| Accounts receivables | 641.5 Thousand | - | -250 Thousand | - | -250 Thousand | 250 Thousand |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | -2.3 Million | -1.4 Million | -3.77 Million | -11.01 Million | -3.77 Million | -1.73 Million |
| Cash at beginning of period | - | - | - | 1.04 Billion | - | - |
| Cash at end of period | 681.24 Million | 681.24 Million | -115.33 Million | 278.6 Million | -115.33 Million | -269.36 Million |
| Capital Expenditure | -657.5 Thousand | -657.5 Thousand | -12.52 Million | -35.41 Million | -12.52 Million | -4.99 Million |
| Effect of forex changes on cash | 218 Thousand | 218 Thousand | - | - | - | - |
| Net cash flow / Change in cash | 681.24 Million | 681.24 Million | -115.33 Million | -769.39 Million | -115.33 Million | -269.36 Million |
| Free Cash Flow | -98.59 Million | -98.59 Million | -114.49 Million | -333.02 Million | -114.49 Million | -51.82 Million |
6083
6899
2493
4295
688329
005257